Background: The role of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in the management glomerular/systemic autoimmune diseases with proteinuria in real-world clinical settings is unclear.
Methods: This is a retrospective, observational, international cohort study. Adult patients with biopsy-proven glomerular diseases were included.